Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Vera Bittner et al.|New England Journal of Medicine|2018Cited by 3.5k
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trialsEllen M. Apperloo, Hiddo J.L. Heerspink, Brendon L. Neuen et al.|The Lancet Diabetes & Endocrinology|2024Cited by 135